Edition:
United Kingdom

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

13.19USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$13.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
994,326
52-wk High
$14.40
52-wk Low
$6.74

Chart for

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $2,368.37
Shares Outstanding(Mil.): 192.24
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Aslan Pharmaceuticals buys full global commercial rights for Varlitinib

* ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA

03 Jan 2018

BRIEF-Array BioPharma Announces Strategic Collaboration With Pfizer

* ARRAY BIOPHARMA ANNOUNCES STRATEGIC COLLABORATION WITH PFIZER

19 Dec 2017

BRIEF-Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes

* ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION

04 Dec 2017

BRIEF-Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting

* Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting

13 Nov 2017

BRIEF-ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018

31 Oct 2017

BRIEF-Array Biopharma announces proposed public offering of common stock

* Array Biopharma announces proposed public offering of common stock

13 Sep 2017

BRIEF-Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

* Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

12 Sep 2017

BRIEF-Array Biopharma appoints Curtis Oltmans as general counsel

* Array Biopharma appoints Curtis Oltmans as general counsel Source text for Eikon: Further company coverage:

14 Aug 2017

BRIEF-Array Biopharma reports Q4 loss per share $0.17

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

09 Aug 2017

BRIEF-Amgen and Array BioPharma announce preclinical license and collaboration agreement

* Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

18 Jul 2017

Earnings vs. Estimates